Description of Research Expertise
Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.
Selected Publications
Yu Kang MD, PhD, Benedicte Lefebvre MD, Ingrid Marti Pamies PhD, Saar I Gill MD, PhD, Abigail G. Doucette MPH, Srinivas Denduluri PhD, Amanda M. Smith MA, Shannon McCurdy MD, Selina Luger MD, Joseph Carver MD, Marielle Scherrer-Crosbie MD, PhD: Symptomatic Heart Failure and Clonal Hematopoiesis–Related Mutations in Patients With Acute Myeloid Leukemia The American Journal of Cardiology : 2024.
Pashna Munshi and Shannon R. McCurdy: Age Barriers in Allogeneic Hematopoietic Cell Transplantation: Raising the Silver Curtain American Journal of Hematology 99 (5): 922-937,2024.
Ashley D. Hadjis and Shannon R. McCurdy: The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation Frontiers in Immunology
15 : 2024.
Jeremy Schmoyer, Ashley D. Hadjis, Griffin W. White, Catherine Lai, and Shannon R. McCurdy: Association of Fried’s frailty phenotype, but not the clinical frailty scale, with overall survival in older adults with acute myeloid leukemia. American Society of Clinical Oncology 42 (16): 2024.
Brendan L. Mangan, PharmD, Clark DuMontier, MD, Judith O. Hopkins, MD, Gregory A. Abel, MD, and Shannon R. McCurdy, MD: Tailoring Therapy in Older Adults with Hematologic Malignancies American Society of Clinical Oncology, Education Book 44 (3): 2024.
Takeshi Onoue, Azin Vakilpour, Yu Kang, Benedicte Lefebvre, Amanda Smith, Shannon R. McCurdy, Joseph R. Carver, Michael Fradley, Jesse Chittams, and Marielle Scherrer-Crosbie: Cardiotoxicity of Venetoclax in Patients with Acute Myeloid Leukemia: Comparison with Anthracyclines Journal of the American College of Cardiology 83 (13): 2024.
Anthony D. Sung, Thuy Koll, Shannon H. Gier, Alessandro Racioppi, Griffin White, Meagan Lew, Marcia Free, Priyal Agarwal, Lauren M. Bohannon, Ernaya J. Johnson, Bharathi Selvan, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, MaryEllen Martin, Alexander E. Perl, Keith W. Pratz, Selina M. Luger, Nelson J. Chao, Shannon R. McCurdy: Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients Transplantation and Cellular Therapy 30 (4): 2024.
Shannon R. McCurdy, Scott R. Solomon, Brian C. Shaffer, Meilun He, Yung-Tsi Bolon, Amanda G. Blouin, Alla Keyzner, Francisco A. Socola, Uroosa Ibrahim, Jun Zou, Hana Safah, Nakhle Saba, Shahinaz Gadalla, Miguel-Angel Perales, Sophie Paczesny, Steven Marsh, Effie W. Petersdorf, Tao Wang, Ephraim J. Fuchs, Stephanie J. Lee: Post-Transplantation Cyclophosphamide Improves Graft-Versus-Host Disease-Free, Relapse-Free Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplant
European Society of Blood and Marrow Transplantation Annual Meeting : B004,2024.
Matthew P. Connor, Neeharika Prathapa, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Ximena Jordan Bruno, Catherine E. Lai, Alison W. Loren, Selina M. Luger, Andrew H. Matthews, Shannon R. McCurdy, Alexander E Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S. Olson, Keith W. Pratz, Daria V. Babushok: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Haematologica : 2024.
Mustafa A. Hyder, Shannon R. McCurdy, Ruby Sabina, Ashley DeVries, Kirstin Chalupa, Natasha Berryman, Jessica Bernhardt, Alison Cusmano, Amy Chai, Rebecca Schwartz, Dimana Dimitrova, Kamil Rechache, Christi McKeown, Jennifer Sponaugle, Noelle Frey, Saar Gill, Elizabeth O. Hexner, Maryellen Martin, Nasheed Hossain, David L. Porter, Alison W. Loren, Jennifer A. Kanakry, Christopher G. Kanakry: Interim Results of a Phase I/II Study of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Matched Bone Marrow Transplantation for Older or Infirm Patients Transplantation and Cellular Therapy, Tandem Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and the CIBMTR : 2024.
View all publications
Academic Contact Information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
12 South Pavilion
Philadelphia,
PA
19104
Patient appointments: 800-789-7366